Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell Sells 368 Shares

Illumina, Inc. (NASDAQ:ILMNGet Rating) SVP Charles Dadswell sold 368 shares of the firm’s stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $300.13, for a total transaction of $110,447.84. Following the completion of the sale, the senior vice president now owns 7,427 shares in the company, valued at approximately $2,229,065.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Monday, March 28th, Charles Dadswell sold 368 shares of Illumina stock. The stock was sold at an average price of $342.83, for a total value of $126,161.44.

Shares of NASDAQ ILMN opened at $300.85 on Tuesday. The business has a fifty day moving average of $333.66 and a two-hundred day moving average of $360.98. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.09 and a current ratio of 2.48. Illumina, Inc. has a 52-week low of $292.51 and a 52-week high of $526.00. The stock has a market cap of $47.26 billion, a PE ratio of 59.57, a PEG ratio of 2.30 and a beta of 0.94.

Illumina (NASDAQ:ILMNGet Rating) last released its quarterly earnings results on Thursday, February 10th. The life sciences company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.25. Illumina had a return on equity of 11.35% and a net margin of 16.82%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the business posted $1.22 earnings per share. The firm’s revenue for the quarter was up 25.2% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 4.14 earnings per share for the current year.

ILMN has been the subject of several research reports. Zacks Investment Research raised Illumina from a “strong sell” rating to a “hold” rating and set a $399.00 target price for the company in a research report on Tuesday, January 4th. Robert W. Baird reduced their target price on Illumina from $437.00 to $380.00 in a research report on Friday, February 11th. Morgan Stanley initiated coverage on Illumina in a research report on Thursday, January 6th. They issued an “equal weight” rating and a $425.00 target price for the company. Barclays raised Illumina from an “underweight” rating to an “equal weight” rating and reduced their target price for the stock from $432.72 to $412.00 in a research report on Tuesday, January 11th. Finally, StockNews.com initiated coverage on Illumina in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $430.10.

A number of hedge funds have recently made changes to their positions in ILMN. AE Wealth Management LLC acquired a new stake in Illumina in the third quarter worth about $231,000. Dupont Capital Management Corp acquired a new stake in Illumina in the third quarter worth about $546,000. PNC Financial Services Group Inc. increased its position in Illumina by 4.7% in the third quarter. PNC Financial Services Group Inc. now owns 54,573 shares of the life sciences company’s stock worth $22,136,000 after purchasing an additional 2,460 shares during the period. Daiwa Securities Group Inc. increased its position in Illumina by 3.9% in the third quarter. Daiwa Securities Group Inc. now owns 14,517 shares of the life sciences company’s stock worth $5,888,000 after purchasing an additional 550 shares during the period. Finally, Citizens Financial Group Inc RI increased its position in Illumina by 28.5% in the third quarter. Citizens Financial Group Inc RI now owns 671 shares of the life sciences company’s stock worth $272,000 after purchasing an additional 149 shares during the period. Hedge funds and other institutional investors own 86.62% of the company’s stock.

About Illumina (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

See Also

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.